ProCE Banner Activity

Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data

Clinical Thought
For a newly diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?

Released: June 21, 2017

Expiration: June 20, 2018

No longer available for credit.

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

ViiV Healthcare

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, Teva, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.